Corvion, Inc.
Webster, TX
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 16910 N Texas Ave A6, Webster, TX 77598, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Bivacor Inc. | Huntington Beach, CA | — |
| Heartpoint Global Inc. | Miami, FL | 339112 Surgical and Medical Instrument Manufacturing |
| Starlight Cardiovascular, Inc. | San Diego, CA | 339112 Surgical and Medical Instrument Manufacturing |
| Unandup, LLC | St. Louis, MO | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
| W-Z Biotech LLC | Lexington, KY | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Corvion, Inc., a for-profit medical-device manufacturer based in Webster, Texas, develops implantable mechanical circulatory support systems for heart failure patients as a federal grant recipient under the National Institutes of Health. The vendor operates exclusively as a prime recipient on National Heart, Lung, and Blood Institute (NHLBI) grants; it holds no federal contracts, IDVs, or subcontract positions in the source data.
Corvion's federal grant portfolio centers on three SBIR Phase II Project Grants from NHLBI (CFDA 93.837, Cardiovascular Diseases Research program) spanning 2022 through 2029. The vendor is developing three distinct implantable blood-pump technologies: a pediatric left ventricular assist device (P-LVAD) enabling home discharge of children awaiting heart transplantation or living long-term with mechanical support, awarded $2,999,968 in August 2026 with performance through July 2029; a totally-implanted left ventricular assist device (TI-LVAD) combining ultra-low-power blood pumps, implantable batteries, and wireless transcutaneous charging to eliminate percutaneous drivelines and external power equipment, awarded in March 2025 with completion in February 2028; and the Nautilus Pump, a minimally invasive partial circulatory support device using magnetic levitation and hydrodynamic bearing technology for low-energy chronic implantation, which completed in February 2023. All three grants target reduction of complications and improved quality of life for heart failure patients by combining hybrid magnetically levitated blood-pump technology with biocompatible engineering suitable for implantation.
Customer concentration is absolute — all three awards (100% of the source portfolio, combined obligated value $5.9 million) fund NHLBI programs. Activity shows one award per year in 2022, 2025, and 2026, with one award (the Nautilus Pump grant) having reached ultimate completion in the past twenty-four months. One award faces recompete within the next twenty-four months. Corvion operates purely as a federal biomedical research grantee with no prime contracting footprint or subcontracting relationships visible in the source data.
Quick answers
Is Corvion, Inc. registered in SAM.gov?
Yes. Corvion, Inc.'s SAM.gov registration is active through April 8, 2027.
What is Corvion, Inc.'s CAGE code?
Corvion, Inc.'s CAGE code is 8FME2, and its Unique Entity ID (UEI) is DP46YALMA9E8.
What is Corvion, Inc.'s most recent federal award?
Corvion, Inc.'s most recent federal grant award is Development of a novel pediatric lvad for home discharge of children awaiting heart transplant (R44HL184709), from National Heart Lung and Blood Institute (NIH), on August 10, 2026.
On GovTribe
See Corvion, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors